Acrivon Therapeutics, Inc.
ACRV • NASDAQ
Acrivon Therapeutics, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Peter Blume-Jensen, with a market cap of $51.5M.
CEOPeter Blume-Jensen
Next Earnings
Upcoming earnings announcement for Acrivon Therapeutics, Inc.
Date
Wednesday, May 13, 2026 (in a month)
Timing
Before Market Open (8:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.51
Revenue Estimate
$774.9K
Earnings History
Past 12 earnings reports for Acrivon Therapeutics, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 19, 2026 | Q4 2025 | -$0.49Est: -$0.47 | -4.3% | -Est: $541.6K | -100.0% |  10-K |
| Nov 13, 2025 | Q3 2025 | -$0.47Est: -$0.58 | +19.0% | - | — | 10-Q |
| Aug 13, 2025 | Q2 2025 | -$0.55Est: -$0.58 | +5.2% | - | — | 10-Q |
| May 14, 2025 | Q1 2025 | -$0.51Est: -$0.64 | +20.3% | - | — | 10-Q |
| Mar 27, 2025 | Q4 2024 | -$0.60Est: -$0.65 | +7.7% | - | — | 10-K |
| Nov 13, 2024 | Q3 2024 | -$0.59Est: -$0.58 | -1.7% | - | — | 10-Q |
| Aug 13, 2024 | Q2 2024 | -$0.52Est: -$0.60 | +13.3% | - | — | 10-Q |
| May 14, 2024 | Q1 2024 | -$0.73Est: -$0.84 | +13.1% | - | — | 10-Q |
| Mar 28, 2024 | Q4 2023 | -$0.86Est: -$0.73 | -17.8% | - | — | 10-K |
| Nov 9, 2023 | Q3 2023 | -$0.66Est: -$0.71 | +7.0% | - | — | — |
| Aug 11, 2023 | Q2 2023 | -$0.63Est: -$0.65 | +3.1% | - | — | 10-Q |
| May 9, 2023 | Q1 2023 | -$0.58Est: -$0.60 | +3.3% | - | — | — |